U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07258836) titled 'A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer' on Nov. 21.
Brief Summary: The purpose of the study is to check how safe and well-tolerated [18F]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Neoplasms
Healthy
Intervention:
DRUG: LY4214835
Administered IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Disclaimer: Curated by HT Syndication....